GlassScriptPhysician profile
Chad R Marsh
NPI 1891065207
$3,579.34
in general payments reported to CMS, 2019-2025
22 companies · $821 in 2025
The $821 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $400 · 2022: $649 · 2023: $1,004 · 2024: $705 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,531.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $920.99 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $678.39 | 2021-2025 | Farxiga, Brilinta, Airsupra |
| Pfizer INC. | $354.50 | 2021-2025 | |
| Abbvie INC. | $345.17 | 2021-2024 | |
| Exact Sciences Corporation | $296.86 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $228.63 | 2021-2023 | Mounjaro, Trulicity, Jardiance |
| Abbott Laboratories | $115.13 | 2023-2025 | Freestyle Libre 3, Amplatzer Amulet, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.41 | 2021-2024 | Jardiance, Tradjenta |
| Amgen INC. | $75.52 | 2021-2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $74.57 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $72.41 | 2021-2025 | |
| Horizon Therapeutics Plc | $59.28 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.49 | 2022 | |
| Esperion Therapeutics, INC. | $38.57 | 2025 | Nexletol |
| Amarin Pharma, INC. | $35.82 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.54 | 2023-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $25.94 | 2023 | Nuedexta |
| Janssen Pharmaceuticals, INC | $24.75 | 2021-2022 | |
| Inspire Medical Systems, INC. | $21.41 | 2024 | Inspire |
| Xeris Pharmaceuticals, INC. | $20.65 | 2023 | Keveyis |
| Insulet Corporation | $19.01 | 2024 | Omnipod |
| Viatris Specialty LLC | $16.30 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.